{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Linagliptin+5mg", "query": { "intervention": "Linagliptin 5mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Linagliptin+5mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T13:08:45.475Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01183013", "title": "30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Pioglitazone 15 mg", "type": "DRUG" }, { "name": "Pioglitazone 45 mg", "type": "DRUG" }, { "name": "Pioglitazone 30 mg", "type": "DRUG" }, { "name": "Linagliptin 5mg / Pioglitazone 45 mg FDC", "type": "DRUG" }, { "name": "Linagliptin 5mg / Pioglitazone 30 mg FDC", "type": "DRUG" }, { "name": "Linagliptin 5mg", "type": "DRUG" }, { "name": "Linagliptin 5mg / Pioglitazone 15 mg FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 936, "start_date": "2010-08", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2014-10-20", "last_synced_at": "2026-09-05T13:08:45.475Z", "location_count": 74, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183013" }, { "nct_id": "NCT01845077", "title": "Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "2x500 mg Metformin (Glumetza)", "type": "DRUG" }, { "name": "5 mg Linagliptin/1000 mg Metformin FDC", "type": "DRUG" }, { "name": "5 mg Linagliptin (Tradjenta)", "type": "DRUG" }, { "name": "3x500 mg Metformin (Glumetza)", "type": "DRUG" }, { "name": "2 x 500 mg Metformin (Glumetza)", "type": "DRUG" }, { "name": "5 mg Linagliptin/1000mg Metformin FDC", "type": "DRUG" }, { "name": "2 x 2.5 mg Linagliptin/750 mg Metformin FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 72, "start_date": "2013-05", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2014-08-19", "last_synced_at": "2026-09-05T13:08:45.475Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01845077" }, { "nct_id": "NCT02061969", "title": "ADA Linagliptin in Long Term Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes" ], "interventions": [ { "name": "linagliptin", "type": "DRUG" }, { "name": "insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2014-04-25", "completion_date": "2017-04-10", "has_results": true, "last_update_posted_date": "2018-08-22", "last_synced_at": "2026-09-05T13:08:45.475Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Decatur, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02061969" }, { "nct_id": "NCT01792518", "title": "MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Linagliptin 5mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 360, "start_date": "2013-02", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-03-06", "last_synced_at": "2026-09-05T13:08:45.475Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Long Beach, California • North Hollywood, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "North Hollywood", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01792518" }, { "nct_id": "NCT00622284", "title": "Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo identical to BI 1356 5mg", "type": "DRUG" }, { "name": "Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg", "type": "DRUG" }, { "name": "BI 1356", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1560, "start_date": "2008-02", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-01-29", "last_synced_at": "2026-09-05T13:08:45.475Z", "location_count": 23, "location_summary": "Tempe, Arizona • Chula Vista, California • Los Angeles, California + 19 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Gatos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00622284" }, { "nct_id": "NCT02467478", "title": "Linagliptin's Effect on CD34+ Stem Cells", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes", "Impaired Renal Function" ], "interventions": [ { "name": "Linagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "George Washington University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "30 Years to 70 Years" }, "enrollment_count": 31, "start_date": "2015-04", "completion_date": "2019-12", "has_results": true, "last_update_posted_date": "2023-01-19", "last_synced_at": "2026-09-05T13:08:45.475Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02467478" }, { "nct_id": "NCT00740051", "title": "A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Linagliptin", "type": "DRUG" }, { "name": "Linagliptin Placebo", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 227, "start_date": "2008-08", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-06-27", "last_synced_at": "2026-09-05T13:08:45.475Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Peoria, Arizona • Greenbrae, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Harbor City", "state": "California" }, { "city": "Huntington Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00740051" }, { "nct_id": "NCT00819091", "title": "Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "BI 1356", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 245, "start_date": "2008-12", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-06-27", "last_synced_at": "2026-09-05T13:08:45.475Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Los Angeles, California • National City, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00819091" }, { "nct_id": "NCT00935220", "title": "Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "linagliptin QD (once daily) for 7 days", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 41, "start_date": "2009-06", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-06-27", "last_synced_at": "2026-09-05T13:08:45.475Z", "location_count": 6, "location_summary": "Cypress, California • DeLand, Florida • Miami, Florida + 3 more", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00935220" }, { "nct_id": "NCT01243424", "title": "CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "linagliptin", "type": "DRUG" }, { "name": "glimepiride", "type": "DRUG" }, { "name": "linagliptin placebo", "type": "DRUG" }, { "name": "glimepiride placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 6103, "start_date": "2010-11-11", "completion_date": "2018-08-21", "has_results": true, "last_update_posted_date": "2020-01-07", "last_synced_at": "2026-09-05T13:08:45.475Z", "location_count": 177, "location_summary": "Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 139 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01243424" } ] }